<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>(1) Rituximab is indicated for the treatment of patients with relapsed or chemoresistant stage III-IV follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>(2) The clinical file is currently limited to 300 patients treated in non comparative trials </plain></SENT>
<SENT sid="2" pm="."><plain>(3) Four infusions of rituximab, at a dose of 375 mg/m2/week, led to at least a partial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response in 50% of these poor-prognosis patients, and prevented disease progression for more than nine months in the responders (median value not yet reached) </plain></SENT>
<SENT sid="3" pm="."><plain>(4) Adverse reactions are frequent and sometimes severe during the first infusion </plain></SENT>
</text></document>